A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective

Introduction: Smoking drives substantial direct health care spending, comprising 8.7% ($168 billion) of annual United States aggregated spending. Smoking cessation (SC) prescription use is an effective strategy to improve health outcomes, increase quit rates, and reduce economic burden. However, patient out-of-pocket costs may limit the use. Health care payers play a vital role in driving use through formulary decisions and copayment policies but must consider both the near-term financial investment as well as downstream effects of increased coverage on health care budgets. This study estimates the return on investment (ROI) of providing Affordable Care Act (ACA)-recommended prescription SC coverage.

Methods: A cost–benefit analysis (CBA) estimates the ROI of providing prescription SC coverage, based on pharmacy costs and savings from smoking-attributable medical expenditures among Medicare, Medicaid, and commercial plan enrollees over 10 years. The CBA incorporated national-level population demographics, smoking prevalence estimates, proportion of smokers attempting to quit, and the utilization of SC products. A five-state Markov chain model simulated patterns of quit attempts, relapse, and cessation assuming two quit attempts per year, no patient cost-sharing, and 25.4% utilization of prescription SC aids. Results include number of quitters, annual pharmacy and smoking-attributable medical costs, and ROI.

Results: After initial investment in SC treatment, smoking-attributable medical benefits accrue over time, generating a positive ROI by year 4 for commercial (11.3%) and Medicaid (78.4%) plans and by year 3 for Medicare (30.6%). Over 10 years, an average return of $1.18, $2.50, and $3.22 savings per dollar spent on SC prescriptions for commercial, Medicaid, and Medicare plans, respectively, may be realized.

Discussion: Given the proven efficacy of SC pharmacotherapy, near-term investments in supporting ACA-recommended SC coverage translate into a positive ROI. As smoking is a leading cause of morbidity and mortality, increased access to prescription SC medications may improve health outcomes and reduce smoking-attributable costs to payers over time.

Keywords: cost–benefit analysis, smoking cessation prescription coverage, smoking-attributable medical cost, return on investment

Introduction

According to the Centers for Disease Control and Prevention (CDC), about 15.1% of US adults (36.5 million) were current smokers in 2015. Despite considerable progress in smoking cessation (SC) efforts over time, smoking remains the leading preventable cause of disease, disability, and death in the USA. Smoking (and exposure to second-hand smoke) may lead to a wide range of diseases such as lung cancer, coronary heart diseases, and pulmonary diseases, and is linked to about one of every five premature

Christine L Baker1
Yao Ding2
Cheryl P Ferrufino3
Stacey Kowal2
Jenen Tan3
Prasun Subedi1

1 Patient & Health Impact, Pfizer, Inc, New York, NY, USA; 2 Health Economics & Outcomes Research, Real World Evidence Solutions, IQVIA, Fairfax, VA, USA; 3 IQVIA, San Francisco, CA, USA
deaths in the USA each year. In addition to the clinical consequences, smoking also has a major economic impact. Smoking continues to be a major contributor to direct health care spending in the USA. Across all US payers, cigarette smoking was associated with 8.7% ($168 billion) of annual aggregated health care spending in 2010. More than 60% of the smoking-attributable spending was paid by public programs, including $45 billion by Medicare (9.6%), $40 billion by Medicaid (15.2%), and $24 billion by other federal health care programs (32.8%). Moreover, the burden of smoking goes beyond direct medical costs to impact society more holistically, with an estimated $107.6 billion indirect cost due to loss of productivity in the USA annually.

SC is one of the most effective strategies to improve health outcomes and reduce health care burden. A recent USA study concluded that if smokers quit before experiencing any symptoms of smoking-related disease, ~70% of their excess medical care costs could be avoided. A majority of current smokers are interested in quitting and attempting to quit, for example, in 2015, 68.0% of current smokers were interested in quitting and 55.4% made a quit attempt in the previous year. However, only 29.0% of those attempting to quit used SC medication therapies (including both prescriptions and over-the-counter [OTC] drugs) as part of their quit attempt. This relatively low utilization of SC therapies limits the success of these quit attempts, as only 5% of smokers who attempt to quit smoking unaided are successful on average. The CDC notes that reducing out-of-pocket (OOP) costs for SC treatments effectively increases patient access to these medications and, therefore, the number of tobacco users who successfully quit. Recent policy initiatives, for example, the Affordable Care Act (ACA) also recommends that group health plans and health insurance issuers provide coverage without patient cost-sharing for 1) screening of all patients for tobacco use; 2) at least two tobacco-cessation attempts per year for enrollees who use tobacco products, with coverage for each quit attempt including four tobacco-cessation counseling sessions, each for a minimum of 10 minutes, including telephone, group, and individual counseling; and 3) coverage for any US Food and Drug Administration (FDA)-approved tobacco-cessation medications (whether prescription or OTC) for a 90-day treatment regimen when prescribed by a health care provider. Patient access to SC therapies, although improving because of these recommendations, remains below recommended levels. A 2015 study found that only 18% of publicly available formularies for state and federal health care marketplaces met the criteria of covering all seven available SC medications without patient cost-sharing. A potential reason could be that the provision of these therapies at no cost to the patient may be viewed as a costly option for health care payers.

Moreover, there is little research that examines whether reduction of smoking rates results in budgetary savings from potential cost offsets. A prior published budget impact model showed relatively low annual budgetary impact of providing coverage for two quit attempts with access to seven types of SC medications with zero patient cost-sharing requirement for Medicare, Medicaid, and commercial plans, but did not address cost offsets and examined trends for a maximum of 5 years. Further, a previously published cost–benefit analysis (CBA) demonstrated substantial savings in a Medicaid SC benefit program in Massachusetts (ie, inpatient savings per participant of $571 [range: $549–$583]). However, this study was limited to a state Medicaid program with a 2-year study time horizon, and was not inclusive of all currently available prescription treatments indicated for SC.

The objective of this study was to estimate the net economic impact of providing SC prescription treatment coverage in both governmental and private health plans. Specifically, a CBA was conducted to estimate the pharmacy costs, medical cost offsets, and overall return on investment (ROI) of providing prescription SC treatment coverage for Medicare, Medicaid, and commercial health plan populations over a longer time horizon of 10 years.

Methods
Overview of model framework
A Markov chain model with five health states was used to simulate patterns of quit attempts, smoking relapse, and cessation success (Figure 1). This closed cohort model has been described in a previous work that estimated the pharmacy budget impact of SC coverage. The model was developed from a payer perspective, and incorporates the Medicare (federal health insurance), Medicaid (jointly funded by the federal government and states), and commercial health plan (employer-sponsored or self-insured) channels. Similar to the previous model, a 6-month model cycle length was utilized. The impact of smoking on morbidity and associated health care costs and resource utilization is multifactorial, with benefits building over time in tandem with increasing risks of key smoking-related comorbidities and avoidable events. As such, a 10-year time horizon was chosen to best balance the need to look beyond a short time frame to capture the impact of changing trajectory of risk with the more medium-term budgetary decision-making utilized by US health care payers who fund SC products.
This study uses a CBA approach to estimate the ROI of providing prescription SC treatments, based on estimated pharmacy costs and savings from smoking-attributable medical expenditures among Medicare, Medicaid, and commercial plan enrollees. The CBA approach incorporated national-level population demographics (ie, the age and gender distribution of the enrollee population in Medicare, Medicaid, and commercial plans), as well as national estimates for the prevalence of smoking, proportion of smokers attempting to quit, and the utilization of SC products to estimate the population of smokers using prescription SC products.

Seven FDA-approved forms of SC prescription products, including five forms of nicotine replacement therapy (NRT) (patch, gum, lozenge, nasal spray, and inhalers) when obtained through prescription and two non-NRT medications (bupropion SR and varenicline), were included in the analysis. The total cost of SC medications was estimated as the sum of per-prescription cost for SC products, multiplied by the number of smokers who are attempting to quit with each product, as derived from the Markov model.

The model estimated the economic benefit of SC products in terms of smoking-attributable medical expenditures, as described below. The net cost savings and ROI of prescription SC treatment by payer type were estimated based on the proportion of health care expenditure covered by each payer (ie, Medicare, Medicaid, and commercial health plans) vs patients’ OOP costs. All costs and medical benefits were adjusted and reported in 2017 US dollars.

Model inputs
Epidemiology estimates, clinical efficacy, and smoking-attributable medical expenditures used in this study were derived from peer-reviewed literature and publicly available data sources. Drug cost, market share, and patient cost-sharing data were obtained from the IQVIA National Prescription Audit™ (NPA) data. Three separate analyses were conducted on a hypothetical health plan with 1 million covered lives from Medicare, Medicaid, or commercial payer perspectives, respectively.

Population distribution
We used the age and gender distribution of the US population from the US census, prevalence of smoking derived from CDC Morbidity and Mortality Weekly Report data, and annual quit attempts and the utilization rate of SC prescriptions collected from the literature to estimate the population of patients using SC medications filled through a prescription (Table 1). The population cohorts were divided into five age bands: 8–17, 18–34, 35–49, 50–64, and 65 or older. The model allowed for patients to age into the next chronologic age group over the 10-year time horizon. As such, demographics for age band of 8–17 were also included in the population calculation to account for members who would age into the 18–34 group over the model’s 10-year time horizon. USA all-cause mortality rates specific by age were utilized to account for deaths in each age band. Differential use of prescription SC products was not available.

![Markov chain diagram](https://www.dovepress.com/)

**Figure 1** Markov chain diagram.

Notes: Health state descriptions:
- **Eligible smoker**: Adult smokers who are eligible to quit smoking with a smoking cessation therapy during the current year. This includes:
  1. smokers who have never attempted to quit,
  2. smokers who have previously attempted to quit and failed,
  3. successful quitters who subsequently relapsed.
- **Ineligible smoker**: This tunnel state is used when modeling one covered quit attempt per year. A tunnel state is a state that can be occupied for only one cycle, which represents both the disease state the individual is in and the number of previous cycles spent in the state. The use of tunnel states helps to build artificial memory in Markov approaches, which normally have no memory over time. This state holds smokers who are not eligible to quit smoking because they failed a quit attempt <12 months prior to their current quit attempt. When modeling two quit attempts per year, smokers return to “Eligible Smoker” in the first cycle after their relapse.
- **Initial quitter**: A tunnel state for smokers who have attempted to quit in the current year, and are currently abstinent from smoking during the current cycle but who have not yet met the criteria for “Successful Quitter”.
- **Successful quitter**: Consists of initial quitters who have abstained from smoking for the required length of time to meet the clinical definition of success and who have not relapsed. The model assumes that a person becomes a “Successful Quitter” after being abstinent from smoking for 1 full year.
- **Dead**: Captures death due to all-cause mortality, based on age- and gender-adjusted rates from US life tables from the Centers for Disease Control and Prevention.

by age group; therefore, a single average value was applied across all ages.

**Smoking cessation prescription utilization, pricing, and cost sharing**

The utilization of SC prescriptions was calculated top–down based on population trends. First, we identified the proportion of smokers attempting to quit, including attempts using SC therapies (prescription or OTC drugs) and attempts made without the assistance of SC therapies (ie, “cold turkey”).

Next, we estimated the percentage of smokers within the plan using SC therapies (prescription and OTC) to quit smoking.

Finally, we took into account the proportion of smokers who used prescription SC prescription products (assumed to be 25.4% across all payer types and age groups) among population using prescription and OTC medications.

By applying the above steps to our population cohorts by age group, the model identifies target smokers for possible intervention. Detailed information on the inputs and patient counts for commercial and Medicaid plans is shown in Table 1. Using similar rates but a restricted age of 65 and above, total patients in the Medicare scenario were 83,603 smokers, 39,461 smokers attempting to quit, 13,298 using SC aids, and 3,378 using prescription smoking aids.

Real-world utilization, pricing, and patient cost sharing of SC prescription products were obtained from the IQVIA NPA data as of February 2017. The IQVIA NPA data is the industry standard for measuring the weekly/monthly outflow of prescriptions from retail pharmacies, mail service houses, or long-term care facilities into the hands of consumers, covering over 90% of all retail pharmacies, up to 75% of mail order and 83% of long-term care prescriptions. Prescription volume data of seven SC prescription products were obtained from the NPA database, which was then transformed back to patient-level utilization by dividing the number of prescriptions by the average number of packs or refills needed per patient to complete a single course of SC therapy (Table 2).

The base-case model evaluates a health care program with open access (no copay) to SC prescriptions, that is, copayment relief under ACA (all FDA-approved tobacco cessation medications be covered without prior authorization or patient cost sharing). Contracted cost per prescription was calculated.
based on drug unit cost, number of units per prescription, and a zero copayment rate under the base-case scenario (Table 2).

Clinical efficacy
Clinical efficacy rates for the seven SC prescription products of interest were based on data from a Cochrane systematic review.23 Unaided cessation success rate (5.0%) and probability of late relapse (recidivism) (4.4%) were derived from published literature.9,24 We used the recidivism rate of 4.4%, an average value of both the primary study results and findings from the secondary studies reported in Wetter et al 2004, to estimate the number of successful quitters who had quit for at least 12 months but then eventually relapsed. More detailed information of efficacy for unaided and aided cessation were described in our previous publication on budget impact of SC.13,24

Smoking-attributable medical cost
To estimate the cost offsets associated with SC, the model utilized smoking-attributable medical costs from the literature to derive the economic value of SC at the population level. Smoking-attributable medical costs per patient by sex and age were originally derived from Maciosek et al 2015, which assumed that 8.66% of USA Personal Health Care Expenditures was attributable to smoking.7 In that paper, the authors calculated smoking-attributable medical expenditures using a relative risk approach, and stratified their analysis by age group, sex, and smoking status (never, current, and former smokers). Because the health benefits of SC accrue over time following the initial quit (decay assumption), in this study, we applied a smooth function provided by Maciosek et al 2017 (1−0.9927−1.086×e^(−0.1171×t)) to calculate the smoking-attributable costs of each former smoker as a portion of a comparable current smoker’s costs taking into account the decay assumption as t=years since quit.25 Furthermore, we reweighted the per-patient cost estimates based on population distribution by our age group categories (eg, 18–34, 35–49, 50–64, and 65+), as shown in Table 3. Using data from Kaiser Family Foundation and other published data sources, the analysis incorporated the proportion of

Table 2 Inputs for market share and drug costs in the base case

<table>
<thead>
<tr>
<th>Product type</th>
<th>Utilization (market share) distribution (%)</th>
<th>Plan cost per prescription (open access, without copay)</th>
<th>Contracted cost per prescriptionb</th>
<th>Prescriptions per therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unit costa</td>
<td>Units per prescriptiona</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial payer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varenicline</td>
<td>74.46</td>
<td>$5.71</td>
<td>55.42</td>
<td>$316.43</td>
</tr>
<tr>
<td>Bupropion</td>
<td>5.12</td>
<td>$0.60</td>
<td>59.76</td>
<td>$35.86</td>
</tr>
<tr>
<td>NRT inhaler</td>
<td>1.48</td>
<td>$1.88</td>
<td>183.93</td>
<td>$345.79</td>
</tr>
<tr>
<td>NRT nasal spray</td>
<td>0.46</td>
<td>$8.34</td>
<td>46.24</td>
<td>$385.67</td>
</tr>
<tr>
<td>NRT gum</td>
<td>3.41</td>
<td>$0.26</td>
<td>135.33</td>
<td>$35.19</td>
</tr>
<tr>
<td>NRT lozenge</td>
<td>1.07</td>
<td>$0.35</td>
<td>120.10</td>
<td>$42.04</td>
</tr>
<tr>
<td>NRT patch</td>
<td>14.00</td>
<td>$1.69</td>
<td>25.23</td>
<td>$42.63</td>
</tr>
<tr>
<td>Medicaid payer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varenicline</td>
<td>40.72</td>
<td>$5.74</td>
<td>53.94</td>
<td>$309.63</td>
</tr>
<tr>
<td>Bupropion</td>
<td>3.63</td>
<td>$0.57</td>
<td>54.85</td>
<td>$31.27</td>
</tr>
<tr>
<td>NRT inhaler</td>
<td>1.59</td>
<td>$1.88</td>
<td>175.43</td>
<td>$329.81</td>
</tr>
<tr>
<td>NRT nasal spray</td>
<td>0.22</td>
<td>$8.32</td>
<td>41.30</td>
<td>$343.65</td>
</tr>
<tr>
<td>NRT gum</td>
<td>15.12</td>
<td>$0.25</td>
<td>129.96</td>
<td>$32.49</td>
</tr>
<tr>
<td>NRT lozenge</td>
<td>3.24</td>
<td>$0.37</td>
<td>117.12</td>
<td>$43.34</td>
</tr>
<tr>
<td>NRT patch</td>
<td>35.48</td>
<td>$1.74</td>
<td>23.83</td>
<td>$41.46</td>
</tr>
<tr>
<td>Medicare payer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varenicline</td>
<td>81.76</td>
<td>$5.73</td>
<td>56.32</td>
<td>$322.69</td>
</tr>
<tr>
<td>Bupropion</td>
<td>8.25</td>
<td>$0.56</td>
<td>68.24</td>
<td>$38.22</td>
</tr>
<tr>
<td>NRT inhaler</td>
<td>4.10</td>
<td>$1.87</td>
<td>190.67</td>
<td>$356.56</td>
</tr>
<tr>
<td>NRT nasal spray</td>
<td>1.65</td>
<td>$8.29</td>
<td>51.19</td>
<td>$42.38</td>
</tr>
<tr>
<td>NRT gum</td>
<td>0.84</td>
<td>$0.29</td>
<td>133.16</td>
<td>$38.62</td>
</tr>
<tr>
<td>NRT lozenge</td>
<td>0.28</td>
<td>$0.39</td>
<td>116.01</td>
<td>$45.24</td>
</tr>
<tr>
<td>NRT patch</td>
<td>3.13</td>
<td>$1.89</td>
<td>24.48</td>
<td>$46.26</td>
</tr>
</tbody>
</table>

Notes: aDrug unit cost and units per prescription were derived from IQVIA National Prescription Audit™ (NPA) data. bContracted cost per prescription was calculated as (Unit Cost × Units per Prescription − Patient Copay).

Abbreviation: NRT, nicotine replacement therapy.
total health care expenditures covered by Medicare (62%),
Medicaid (95.2%), or commercial payers (81.9%) vs by
patients’ OOP spending or other sources, respectively, to
isolate costs to payers.

Assumptions and key outcome measures
Our study made the following assumptions: First, popula-
tion demographics, proportion of patients attempting to
quit, proportion using SC prescription products, and market
share distribution of the seven SC prescription products
were consistent over the 10-year time horizon. Second, all
smokers who attempt to quit entered the model to account
for smokers who may successfully quit without SC therapies.
Third, because published data suggest that relapse decreases
as the duration of time since quitting increases, the model
assumes that a person becomes a “Successful Quitter” after
being abstinent from smoking for at least one full year and a
single rate is used for late relapse among successful quitters
irrespective of time since quitting. Fourth, drug unit cost
per pill derived from NP A data includes the dispensing fee.
Therefore, dispensing fee was assumed to be included in the
overall prescription cost. Fifth, we assumed the same utili-
ization of SC prescription products to quit smoking (25.4%)
across age groups, scenarios, and payer types in the base
case. This percentage was used to calculate the percentage
of “eligible” population for the model (ie, smokers who are
attempting to quit annually with prescription products). In
addition, the economic outcomes are at the population level,
accounting for the status of current or former smokers in the
population at the start of the simulation, and evaluates the
population benefits accruing thereafter over time. Finally,
in the base case, the model assumes a decay assumption as
previously described with this economic data for estimating
the accumulated health benefits associated with SC over time
since initial quitting.

The following key outcome measures were estimated
in this analysis: total number of successful quitters, total
cost of SC medication, medical benefit (cost) of quitting,
et economic benefit of quitting, and the ROI to a plan for
providing SC benefit. The total number of successful quitters
consists of initial quitters who have abstained from smoking
for the required length of time to meet the clinical defini-
tion of success and who have not relapsed. By definition,
a successful quitter must quit for at least 12 months before
becoming a successful quitter. Detailed calculation steps of
other key outcome measures are described in the legends
for Figures 2–4.

Base-case model scenario
The base-case scenario was defined as the provision of two
smoking quit attempts per year, with no associated copay, and
a 25.4% utilization rate of SC prescriptions. This scenario
reflects the ACA recommendation of allowing up to two quit
attempts per year with no patient cost sharing. The results
for the base-case scenario from the three payer channels
(ie, commercial, Medicaid, and Medicare) are reported in
this paper to highlight the potential ROI for a plan with the
ACA-recommended coverage.

Statement for ethics
Most of the data sources are publicly available, except
for the IQVIA National Prescription Audit™ (NPA) data.
No IRB approval was needed for this study given that no
human subjects were included. This is an economic model
developed from secondary data. Unpublished data from this
study, specifically market share and daily average consump-
tion data for prescription smoking cessation products, can
be made available to editors and reviewers upon request to
the corresponding author.

Results
For hypothetical nationally representative commercial or
Medicaid plans consisting of 1 million covered lives, ~63,049
adult smokers in each plan will attempt to quit in a given year.
Of those attempting to quit, ~16,595 smokers will use smoking
cessation therapies (either prescription or OTC drug), of

---

Table 3 Annual smoking-attributable medical costs per patient

<table>
<thead>
<tr>
<th>Age group</th>
<th>Current smokers</th>
<th>Former smokers</th>
<th>Incremental cost</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
<td>Males</td>
</tr>
<tr>
<td>18–34</td>
<td>$1,639.82</td>
<td>$1,539.56</td>
<td>$1,000.99</td>
</tr>
<tr>
<td>35–49</td>
<td>$1,639.82</td>
<td>$1,539.56</td>
<td>$1,000.99</td>
</tr>
<tr>
<td>50–64</td>
<td>$4,213.54</td>
<td>$3,416.82</td>
<td>$2,572.07</td>
</tr>
<tr>
<td>65+</td>
<td>$13,555.14</td>
<td>$12,424.74</td>
<td>$8,274.45</td>
</tr>
</tbody>
</table>

Note: Smoking-attributable medical expenditures were adjusted to 2017 US$.
which only 4,215 will utilize smoking cessation prescription products (Table 1). For a hypothetical Medicare plan consisting of 1 million enrollees, 13,298 of 39,461 smokers aged above 65 will attempt to quit using smoking cessation therapies (prescription or OTC), of which only 3,378 will utilize smoking cessation prescriptions.

In the base case (two covered quit attempts and no patient cost-sharing), the total number of successful quitters using smoking cessation prescription products over 10 years were estimated to be 6,853 for commercial payers, 6,115 for Medicaid, and 4,986 for Medicare plans.

Over the 10-year time horizon, the number of new successful quitters will decrease annually because of the decreasing number of prevalent smokers in each subsequent year (given accumulating successful quits as well as mortality). Therefore, the total drug costs of smoking cessation prescriptions decrease over time (represented by the green line in Figures 2–4). On the other hand, the medical benefits attributable to former smokers accrue with a steady increasing trend and a slightly declining trend for the total prescription costs, thereby increasing the net health benefit to the plan (Figures 2–4). The ROI would gradually increase from a negative value in the first year to a positive value (11.3% for commercial plan and 78.4% for Medicaid plan with a net economic benefit of $327,579 and $1,469,834, respectively) in the fourth year since quitting. For Medicare payer, the ROI has become a positive value of 30.6% ($801,132 net economic benefit) from the third year since smoking cessation.

On average, over the 10-year follow-up, the provision of up to two quit attempts per year with no patient cost sharing will yield a return of $1.18, $2.50, and $3.22 savings for every dollar spent on smoking cessation prescriptions for commercial, Medicaid, and Medicare plans.
Medicaid, and Medicare plans, respectively. The relatively higher ROI for Medicare vs. commercial and Medicaid plans, is driven by the higher annual direct health care costs in the older Medicare population, and, therefore, the higher associated potential cost offsets from smoking cessation.

Univariate sensitivity analysis (testing a range of 20% above and below default values) was performed on key variables to test the impact of changing input assumptions on model results. Model results consistently showed ROI above 100% across all three payer perspectives across changes to key inputs, highlighting that the model results of a positive ROI are robust. The model was most sensitive to the exclusion of the decay assumption when estimating smoking-attributable costs, and followed by the percentage of total health care expenditures covered by the payer. The exclusion of the decay assumption assumes an average health benefit value, regardless of time since quit. When the decay assumption is excluded, the average increase in ROI over 10 years was 240.7%, 535.8%, and 446.8% for commercial, Medicare, and Medicaid plans, respectively.

**Discussion**

In this study, we analyzed the benefits of providing smoking cessation prescription medications in a health care program with two smoking quit attempts per year and no copayment (or the ACA recommended coverage scenario). We reported that smoking cessation treatment would enable 6,853 smokers for commercial, 6,115 for Medicaid, and 4,986 for Medicare plans to quit over 10 years. The model demonstrated that ROI became positive by year 3 for Medicare and by year 4 for commercial and Medicaid. Looking at the total investment...
over 10 years, for each dollar invested in smoking cessation prescription products, the average net economic benefit for return is up to $3.22 dollars per year (for Medicare plans) over 10 years.

The findings of this study resonate with other publications that have examined ROI for smoking cessation programs. However, results from this work build on the existing literature to show a holistic picture of cost impact, considering both the cost of smoking cessation medications as well as estimated cost offsets over an extended time horizon that better captures the medium to long-term impact of smoking cessation. For example, a study on the Massachusetts Medicaid Cessation Benefit program showed that the state saved $571 in inpatient costs per participant, for about $183 per participant in program costs. Savings in medical costs were estimated to be $3.12 for every $1 spent on the Medicaid cessation program, yielding an ROI of $2.12 per $1 spent. Our study expanded the scope of analysis from a state Medicaid program to a national study, lengthened the time horizon from 2 to 10 years, and included FDA-approved smoking cessation medications not included in the Massachusetts study, which were unavailable at the time of the study. Consistent with the Massachusetts study, our findings suggest positive cost savings (net benefits) with ACA-recommended smoking cessation program, yielding an average return of $2.50 for Medicaid with ROI ranging from $0.96 (year 1) to $8.68 (year 10).

Further, a previously published budget impact model for smoking cessation programs estimated that the per-member per-month (PMPM) cost of providing coverage of smoking
cessation medications was $0.10 for commercial, $0.06 for Medicare, and $0.07 for Medicaid plans (assuming 7.4% utilization rate of smoking cessation prescription products). This study builds on that work to incorporate potential cost benefits and to evaluate how expenditures would change with a higher utilization of prescription medications (a 25.4% rate). Putting the findings of this study into a PMPM context, we found that the monthly cost of smoking cessation prescription products per member ranges from $0.30 (year 1) to $0.18 (year 10) in a comprehensive coverage scenario with no copay. The difference in PMPM estimates between the two studies is a result of the increased utilization rate as well as minor drug cost changes in the current analysis. Using an assumed utilization rate of 7.4% in this updated model, PMPM estimates for year 1 (and on average over the 10 years) are in line with projections from the previously published BIM for commercial ($0.09 year 1; $0.08 10-year average), Medicare ($0.08; $0.07), and Medicaid ($0.06; $0.05). A lower utilization of 7.4% decreases the ROI to $1.18, $2.49, and $3.20 savings for every dollar spent on smoking cessation prescriptions for commercial, Medicaid, and Medicare plans compared to the base-case scenario over 10 years.

Similar to any economic model, this CBA is subject to several limitations, which should be considered when interpreting results. First, the data on utilization and costs for smoking cessation intervention are based on real-world estimates derived from the IQVIA NPA data. While this dataset covers most of the prescription channels (pharmacy retail, mail order), it only covers prescriptions across 86% of all standard and specialty markets and projects the remaining 14%. Second, the model relies on the use of published efficacy rates derived from systematic reviews and meta-analyses for indirect comparison given that head-to-head trial data are not available for all comparators in the analysis. Third, the model only estimates the costs and benefits associated with the use of smoking cessation prescription products. However, in the real world, many smokers will attempt to quit either unaided or using nonprescription OTC products and they may also utilize behavioral counseling programs (either individual or group), which will enhance their likelihood of success resulting in greater economic savings. In such cases, the plan would gain additional economic benefit without a direct cost incurred, and therefore, the overall net economic benefit reported in this model may be underestimated. Fourth, the analysis does not account for drug adherence – it assumes that all patients who attempt to quit undergo a full course of therapy as prescribed. Fourth, the analysis does not explore health care resource utilization changes that may result from the removal of patient cost sharing. Finally, given data gaps in estimating the use of prescription smoking cessation products by age, the model uses an average of 25.4% across all age groups. However, sensitivity analyses confirm that changes to population inputs (such as the percent of patients using smoking cessation medication) only scale the magnitude of costs and does not impact the relationship between costs and ROI in a meaningful way. Therefore, we concluded that the need to use a single estimate across age groups did not impact the overall interpretation of ROI.

Our study directly estimates the ROI of adopting ACA-recommended smoking cessation coverage to a hypothetical US health plan (commercial, Medicaid, or Medicare). Given the proven efficacy of pharmacotherapy for smoking cessation, near-term investments in supporting the ACA-recommended smoking cessation benefits will translate into a positive long-term ROI. As smoking is a leading cause of morbidity and preventable deaths in the USA, the availability of smoking cessation benefits could not only improve health outcomes (e.g., reduced smoking-associated comorbidities and better health-related quality of life), but also reduce smoking-attributable costs to payers over time. As such, public health initiatives such as Healthy People 2020,26 the ACA, and the National Academy of Medicine identified tobacco control and chronic disease prevention as one of the key issue areas for vital directions for health and health care.27 While information on improvements in patient outcomes and patient quality of life resonate with patients, providers, and health care payers alike, health care payers must consider the fiscal burden of the initial investment in smoking decisions when operating within tight budgets. Therefore, it is important to consider the value of health care interventions both in terms of patient outcomes and in terms of economic impact. Findings of this study reinforce that adopting the ACA recommendations for smoking cessation coverage will have a limited near-term impact on health plans and significant potential long-term benefits.

Conclusion
The results of this analysis are consistent with prior research, which has demonstrated the efficacy and cost-effectiveness of certain drug therapies in reducing smoking and the health benefits of smoking cessation.28 Furthermore, utilizing real-world data, this study provides health care payers with a benchmark analysis regarding the economic benefit and ROI of investing in smoking cessation programs as they strive to balance health outcomes and costs, and illustrates...
the potential financial impact of short-term investments on longer-term savings.

Data sharing statement
Unpublished data from this study, specifically market share and daily average consumption data for prescription smoking cessation products, can be made available to editors and reviewers upon request to the corresponding author.

Acknowledgments
Sponsorship, article processing charges, and the open access charge for this study were funded by Pfizer Inc.

Author contributions
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure
CL Baker and P Subedi are employees and stockholders of Pfizer Inc. CP Ferrufino, Y Ding, J Tan, and S Kowal are employees of IQVIA, which received funding from Pfizer for conducting this study and for the development of this manuscript. The authors report no other conflicts of interest in this work.

References